Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07446439
PHASE3

A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use

Sponsor: Vanda Pharmaceuticals

View on ClinicalTrials.gov

Summary

The goal of this study is to measure the effects of using Tradipitant to treat nausea and vomiting induced by GLP-1R agonist use in adults with class I or class II obesity, or adults who are overweight with at least one weight-related condition. The study is placebo-controlled with two treatment arms.

Official title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Tradipitant on Nausea and Vomiting After GLP-1R Agonist Administration in Healthy Overweight or Obese Volunteers

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

280

Start Date

2026-02-25

Completion Date

2026-12-01

Last Updated

2026-03-03

Healthy Volunteers

Yes

Interventions

DRUG

Tradipitant

Oral Capsule

DRUG

Placebo

Oral Capsule

Locations (2)

Vanda Investigational Site

Los Angeles, California, United States

Vanda Investigational Site

New York, New York, United States